Upon joining the study, you will attend an initial visit where your eligibility will be confirmed. This includes reviewing your medical history and ensuring you meet the study criteria.

You will be asked to demonstrate proper inhaler technique. If needed, training will be provided to ensure correct usage before the study begins.

Your current asthma control will be assessed using a questionnaire. This will help determine your starting point for the study.

At the start of the study, you will begin receiving the medication tezepelumab. This is administered as a subcutaneous injection, which means it is injected under the skin.

The dosage is 210 mg of tezepelumab, given once every four weeks. This will continue throughout the study duration.

You will have regular follow-up visits to monitor your asthma control and overall health. These visits will occur at specified intervals throughout the study.

During these visits, your asthma symptoms will be assessed, and any changes in your condition will be recorded.

At week 24, your asthma control will be evaluated to determine if you have achieved control or have low biomarkers. This assessment will help decide the next steps in your treatment plan.

If you have demonstrated asthma control by week 24, there may be an opportunity to reduce your background asthma therapy while maintaining control.

This phase aims to assess the potential for reducing daily asthma medication without losing control over your asthma symptoms.

At the end of the study, around week 56, a final assessment will be conducted to evaluate your asthma control and the effectiveness of the treatment.

The goal is to determine if you have successfully reduced your daily asthma medication while maintaining control over your symptoms.